Hepion Pharmaceuticals (HEPA) Competitors $0.07 0.00 (-0.44%) As of 07/3/2025 12:55 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock HEPA vs. ONVO, SPRC, EVAX, ZVSA, SXTP, NBY, GENE, PALI, PPBT, and SPRBShould you be buying Hepion Pharmaceuticals stock or one of its competitors? The main competitors of Hepion Pharmaceuticals include Organovo (ONVO), SciSparc (SPRC), Evaxion A/S (EVAX), ZyVersa Therapeutics (ZVSA), 60 Degrees Pharmaceuticals (SXTP), NovaBay Pharmaceuticals (NBY), Genetic Technologies (GENE), Palisade Bio (PALI), Purple Biotech (PPBT), and Spruce Biosciences (SPRB). These companies are all part of the "pharmaceutical products" industry. Hepion Pharmaceuticals vs. Its Competitors Organovo SciSparc Evaxion A/S ZyVersa Therapeutics 60 Degrees Pharmaceuticals NovaBay Pharmaceuticals Genetic Technologies Palisade Bio Purple Biotech Spruce Biosciences Hepion Pharmaceuticals (NASDAQ:HEPA) and Organovo (NASDAQ:ONVO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, profitability and analyst recommendations. Which has more volatility & risk, HEPA or ONVO? Hepion Pharmaceuticals has a beta of 1.69, meaning that its stock price is 69% more volatile than the S&P 500. Comparatively, Organovo has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Do insiders and institutionals believe in HEPA or ONVO? 17.2% of Hepion Pharmaceuticals shares are held by institutional investors. Comparatively, 8.2% of Organovo shares are held by institutional investors. 0.1% of Hepion Pharmaceuticals shares are held by insiders. Comparatively, 3.7% of Organovo shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is HEPA or ONVO more profitable? Hepion Pharmaceuticals has a net margin of 0.00% compared to Organovo's net margin of -10,151.64%. Organovo's return on equity of -346.26% beat Hepion Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Hepion PharmaceuticalsN/A -812.56% -207.31% Organovo -10,151.64%-346.26%-187.53% Which has stronger earnings & valuation, HEPA or ONVO? Organovo has higher revenue and earnings than Hepion Pharmaceuticals. Hepion Pharmaceuticals is trading at a lower price-to-earnings ratio than Organovo, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHepion PharmaceuticalsN/AN/A-$48.93M-$219.000.00Organovo$122K0.00-$14.67M-$10.20N/A Does the media favor HEPA or ONVO? In the previous week, Hepion Pharmaceuticals had 1 more articles in the media than Organovo. MarketBeat recorded 1 mentions for Hepion Pharmaceuticals and 0 mentions for Organovo. Hepion Pharmaceuticals' average media sentiment score of 0.40 beat Organovo's score of 0.00 indicating that Hepion Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Hepion Pharmaceuticals Neutral Organovo Neutral SummaryHepion Pharmaceuticals and Organovo tied by winning 6 of the 12 factors compared between the two stocks. Get Hepion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for HEPA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HEPA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HEPA vs. The Competition Export to ExcelMetricHepion PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$738K$839.46M$5.56B$9.04BDividend YieldN/A4.84%5.24%4.01%P/E Ratio-0.021.1527.6120.24Price / SalesN/A228.55417.30118.22Price / CashN/A23.4436.8958.10Price / Book0.056.328.035.67Net Income-$48.93M-$27.99M$3.18B$249.21M7 Day PerformanceN/A2.11%2.93%3.28%1 Month PerformanceN/A10.13%3.75%5.55%1 Year PerformanceN/A11.60%35.20%21.09% Hepion Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HEPAHepion Pharmaceuticals0.6972 of 5 stars$0.07-0.4%N/A-99.9%$738KN/A-0.0220Gap DownONVOOrganovoN/AN/AN/AN/A$3.47M$122K-2.4020Gap UpSPRCSciSparc0.4643 of 5 stars$0.31+1.0%N/A-59.4%$3.46M$1.31M0.004Stock SplitEVAXEvaxion A/S2.3105 of 5 stars$2.45flat$10.00+308.2%-84.7%$3.44M$3.34M-2.1160ZVSAZyVersa Therapeutics0.5853 of 5 stars$0.68-5.0%N/A-81.4%$3.40MN/A0.002SXTP60 Degrees Pharmaceuticals2.1024 of 5 stars$2.37+3.0%$7.00+195.4%+106.6%$3.39M$300K-0.053News CoverageGap UpNBYNovaBay Pharmaceuticals2.0383 of 5 stars$0.58-4.3%$0.85+46.6%-71.0%$3.37M$9.78M-0.0130GENEGenetic TechnologiesN/A$0.77flatN/AN/A$3.37M$7.66M0.0050High Trading VolumePALIPalisade Bio1.6722 of 5 stars$0.68-2.8%$12.00+1,664.4%-83.3%$3.36M$250K-0.1010PPBTPurple Biotech2.4285 of 5 stars$2.35+0.4%$33.00+1,304.3%N/A$3.11MN/A-0.9020Gap UpSPRBSpruce Biosciences2.1805 of 5 stars$0.07+0.7%$1.75+2,313.8%-87.2%$3.06M$4.91M-0.0820News CoverageGap Down Related Companies and Tools Related Companies ONVO Alternatives SPRC Alternatives EVAX Alternatives ZVSA Alternatives SXTP Alternatives NBY Alternatives GENE Alternatives PALI Alternatives PPBT Alternatives SPRB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HEPA) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hepion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hepion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
